Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Slides:

Advertisements

Similar presentations

Acute Myeloid Leukemia

Advertisements

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

by David Grimwade, Adam Ivey, and Brian J. P. Huntly

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia by Philipp A. Greif, Annika.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

Anthracycline Dose Intensification in Acute Myeloid Leukemia

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

A novel hierarchical prognostic model of AML solely based on molecular mutations by Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane.

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Epigenetic heterogeneity is associated with genetic heterogeneity in CLL samples. Epigenetic heterogeneity is associated with genetic heterogeneity in.

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML by Nona Shayegi, Michael Kramer,

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features by Maria E. Figueroa, Bas J.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

by R. Coleman Lindsley, and Benjamin L. Ebert

Global approach to the diagnosis of leukemia using gene expression profiling by Torsten Haferlach, Alexander Kohlmann, Susanne Schnittger, Martin Dugas,

Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation Miguel Waterhouse, Dietmar Pfeifer, Milena Pantic,

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

by Gregory H. Underhill, David George, Eric G. Bremer, and Geoffrey S

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

by Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, Maria G

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

by Alex Aleshin, and Peter L. Greenberg

Impact of somatic and germline mutations on the outcome of systemic mastocytosis by Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason.

Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Aaron T. Gerds, Matthew J. Walter, Bart L. Scott

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

by Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad F

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Significant gynecological bleeding in women with low von Willebrand factor levels by Michelle Lavin, Sonia Aguila, Niall Dalton, Margaret Nolan, Mary Byrne,

Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications by Daria V. Babushok, Jamie L. Duke,

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL by Sabah Kadri, Jimmy Lee, Carrie Fitzpatrick,

Significant differences in translational efficiencies of DNA damage repair pathway genes between patient clusters. Significant differences in translational.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers by Debargh Dutta, Devi Gunasekera,

Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia by Heiko Becker, Gabriele Greve, Keisuke Kataoka,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine by Raphaelle Fanciullino, Laure Farnault, Mélanie.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Translational efficiency of ATM, MRN complex, and RIF1.

DNMT3A2 signatures are coherently modified in AML.

Kinetics of clone appearance, size, persistence, and lineage content.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz,

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy by Guillermo Montalban-Bravo,

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Impact of age on clinical risk scores in follicular lymphoma

Fig. 4 Identification of C

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

How I treat T-cell acute lymphoblastic leukemia in adults

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Presentation transcript:

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour, Maja Rothenberg-Thurley, Tanja Hinrichsen, Bianka Ksienzyk, Sebastian Tschuri, Stephanie Schneider, Eva Hoster, Wolfgang E. Berdel, Bernhard J. Woermann, Maria C. Sauerland, Jan Braess, Stefan K. Bohlander, Hanns-Georg Klein, Wolfgang Hiddemann, Klaus H. Metzeler, and Karsten Spiekermann BloodAdv Volume 2(20):2724-2731 October 23, 2018 © 2018 by The American Society of Hematology

Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology

Mutation spectrum of moCEBPA, biCEBPA, and wtCEBPA. Mutation spectrum of moCEBPA, biCEBPA, and wtCEBPA. Evaluation of the mutation spectrum of moCEBPA (n = 32) and biCEBPA (n = 48) patients in comparison with wtCEBPA samples (n = 287). Eight of 20 genes with a mutation frequency of ≥5% were significantly associated with ≥1 groups. Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology

Frequency of genetic alterations organized by categories of related genes and genetic groups. Frequency of genetic alterations organized by categories of related genes and genetic groups. The heatmap includes all genes that were mutated in either the moCEBPA (red) or biCEBPA (dark blue) subgroup. biCEBPA patient samples were further separated in 2 biological groups: CCSneg (blue) and CCSpos (green). Patients with a signal ratio of FLT3-ITD ≥0.5 are marked with an asterisk. Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology

Age and CR rate of biCEBPACCSpos, biCEBPACCSneg, and moCEBPA patients. Age and CR rate of biCEBPACCSpos, biCEBPACCSneg, and moCEBPA patients. (A) Age of biCEBPACCSneg (median = 48), biCEBPACCSpos (median = 66), and moCEBPA (median = 62) patients. Scatter dot plot, median with interquartile range. (B) The CR rate was significantly higher in biCEBPACCSneg patients (91% [20/22]) than biCEBPACCSpos (61% [14/23]; P = .035) and moCEBPA patients (P = .027). Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology

Survival data depending on biogroup and TET2 status. Survival data depending on biogroup and TET2 status. (A) OS of biCEBPACCSneg, biCEBPACCSpos, and moCEBPA patients. (B) OS of biCEBPA patients depending on TET2 mutational status. Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology

Mutational status of biCEBPACCSpos and biCEBPACCSneg remission samples (age is given in brackets). Mutational status of biCEBPACCSposand biCEBPACCSnegremission samples (age is given in brackets). (A) Four out of 5 biCEBPACCSpos patients had persisting clones in CR, indicating a clonal hematopoiesis. (B) None of the 5 biCEBPACCSneg samples had a detectable mutation load at the time of remission. Dx, diagnosis. Nikola P. Konstandin et al. Blood Adv 2018;2:2724-2731 © 2018 by The American Society of Hematology